Q32 Bio Inc. (QTTB) stock
QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.53−0.10 (-1.16%)
Close on Nov 18, 2026Market cap $253.93MP/E –Yield –
Q32 Bio total assets
Total assets on the balance sheet at the end of each period.
Q32 Bio's total assets was $115.87M at Jun 30, 2026. For fiscal 2025 it was $61.78M, down 33.1% from the year before. The highest annual figure on record is $310.57M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.78M | -33.1% |
| FY2024 | Dec 31, 2024 | $92.33M | +96.2% |
| FY2023 | Dec 31, 2023 | $47.06M | -79.4% |
| FY2022 | Dec 31, 2022 | $228.47M | +7.9% |
| FY2021 | Dec 31, 2021 | $211.72M | -19.7% |
| FY2020 | Dec 31, 2020 | $263.74M | -15.1% |
| FY2019 | Dec 31, 2019 | $310.57M | +19.9% |
| FY2018 | Dec 31, 2018 | $259.09M | +88.4% |
| FY2017 | Dec 31, 2017 | $137.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $115.87M | +75.2% |
| Q1 FY2026 | Mar 31, 2026 | $63.68M | -19.5% |
| Q4 FY2025 | Dec 31, 2025 | $61.78M | -33.1% |
| Q3 FY2025 | Sep 30, 2025 | $57.78M | -44.7% |
| Q2 FY2025 | Jun 30, 2025 | $66.12M | -46.8% |
| Q1 FY2025 | Mar 31, 2025 | $79.07M | -48.1% |
| Q4 FY2024 | Dec 31, 2024 | $92.33M | +96.2% |
| Q3 FY2024 | Sep 30, 2024 | $104.54M | -25.4% |
| Q2 FY2024 | Jun 30, 2024 | $124.21M | -26.7% |
| Q1 FY2024 | Mar 31, 2024 | $152.33M | -23.0% |
| Q4 FY2023 | Dec 31, 2023 | $47.06M | -79.4% |
| Q3 FY2023 | Sep 30, 2023 | $140.06M | -46.7% |
| Q2 FY2023 | Jun 30, 2023 | $169.34M | -40.5% |
| Q1 FY2023 | Mar 31, 2023 | $197.88M | -36.4% |
| Q4 FY2022 | Dec 31, 2022 | $228.47M | +7.9% |
| Q3 FY2022 | Sep 30, 2022 | $262.65M | +13.8% |
| Q2 FY2022 | Jun 30, 2022 | $284.61M | +9.9% |
| Q1 FY2022 | Mar 31, 2022 | $310.96M | +32.5% |
| Q4 FY2021 | Dec 31, 2021 | $211.72M | -19.7% |
| Q3 FY2021 | Sep 30, 2021 | $230.82M | +1.1% |
| Q2 FY2021 | Jun 30, 2021 | $258.92M | +0.3% |
| Q1 FY2021 | Mar 31, 2021 | $234.70M | -18.7% |
| Q4 FY2020 | Dec 31, 2020 | $263.74M | -15.1% |
| Q3 FY2020 | Sep 30, 2020 | $228.36M | -27.9% |
| Q2 FY2020 | Jun 30, 2020 | $258.24M | -24.3% |
| Q1 FY2020 | Mar 31, 2020 | $288.79M | +23.9% |
| Q4 FY2019 | Dec 31, 2019 | $310.57M | +19.9% |
| Q3 FY2019 | Sep 30, 2019 | $316.76M | +18.0% |
| Q2 FY2019 | Jun 30, 2019 | $341.16M | +26.2% |
| Q1 FY2019 | Mar 31, 2019 | $233.03M | +80.5% |
| Q4 FY2018 | Dec 31, 2018 | $259.09M | +88.4% |
| Q3 FY2018 | Sep 30, 2018 | $268.40M | – |
| Q2 FY2018 | Jun 30, 2018 | $270.31M | – |
| Q1 FY2018 | Mar 31, 2018 | $129.08M | – |
| Q4 FY2017 | Dec 31, 2017 | $137.53M | – |
See a number that looks wrong?